Callisto Pharmaceuticals Inc.

callisto pharmaceuticals inc. - All News and Analysis

• Callisto Pharmaceuticals Announces Presentation on SP-304 at the 3rd International Congress on Natural Peptides to Drugs

  - 2008-04-15

  NEW YORK -- Callisto Pharmaceuticals, Inc. (AMEX: KAL; FWB: CA4), a developer of new drug treatments in the fight against cancer and gastrointestinal disorders, announced today that Dr. Kunwar Shailubhai, Sr. VP Discovery Research, will give a plenary talk covering therapeutic applications of guanylate cyclase C agonist peptides at the...

  Tags: Callisto Pharmaceuticals Inc., Company, Dr., HEALTHCARE, U.S. Congress

• Publication of Early Research on Callisto Pharmaceutical's Degrasyn Drug Class Suggests Potential to Treat Brain Tumors.(Drug overview)

  - 2007-01-23

  NEW YORK, January 23 /PRNewswire/ -- - Paper Published in Oncogene Highlights Animal Model Data on Degrasyn Drug Candidate WP1066 Callisto Pharmaceuticals, Inc. (Amex: KAL - News; FWB: CA4), a developer of new drug treatments in the fight against cancer and other...

  Tags: agent, Benefits, Callisto Pharmaceuticals Inc., HEALTHCARE, SOFTWARE, University of Texas

• Callisto Pharmaceuticals' Clinical Study of Atiprimod in Multiple Myeloma Patients Expanded to Additional Clinical Site.

  - 2006-07-27

  NEW YORK, July 27 /PRNewswire/ -- - University of Michigan Comprehensive Cancer Center Commences Enrollment of Multiple Myeloma Patient in Phase I/IIa Clinical Trial Callisto Pharmaceuticals, Inc. (Amex: KAL)(FWB:CA4), a developer of new drug treatments in the fight against cancer and other...

  Tags: Callisto Pharmaceuticals Inc., HEALTHCARE, patient, University of Michigan

• Callisto Announces Sponsored Laboratory Study Agreement With M. D. Anderson Cancer Center on Degrasyn Anticancer Agents.

  - 2006-06-15

  NEW YORK, June 15 /PRNewswire/ -- - Research Agreement to Support Biological Studies on New Tumor-Fighting Class of Drugs Callisto Pharmaceuticals, Inc. (Amex: KAL; FWB: CA4), a developer of new drug treatments in the fight against cancer and other major health...

  Tags: agreement, Callisto Pharmaceuticals Inc., compound, Dr., HEALTHCARE, University of Texas

• HNP, KAL, NETC Have Been On BUYINS.NET Naked Short List For 13 Consecutive Trading Days.

  - 2005-08-19

  M2 PRESSWIRE-19 August 2005-BUYINS.NET: HNP, KAL, NETC Have Been On BUYINS.NET Naked Short List For 13 Consecutive Trading DaysC1994-2005 M2 COMMUNICATIONS LTD RDATE:19082005 www.buyins.net, announced today that these select companies have been on the NASDAQ, AMEX and NYSE naked short threshold...

  Tags: AMEX, Cable, Callisto Pharmaceuticals Inc., FINANCE, Investment, Nasdaq Stock Market Inc., New York Stock Exchange, SECURITY, TELECOMMUNICATIONS

• GIGA, HNP, KAL, NETC, STLW, VSL have been added to naked short lists today.

  - 2005-08-03

  M2 PRESSWIRE-3 August 2005-BUYINS.NET: GIGA, HNP, KAL, NETC, STLW, VSL have been added to naked short lists todayC1994-2005 M2 COMMUNICATIONS LTD RDATE:03082005 BUYINS.NET, www.buyins.net, announced today that these select companies have been added to the NASDAQ, AMEX and NYSE naked short...

  Tags: Amex, cable, Callisto Pharmaceuticals Inc., fiber-optics, microwave, Nasdaq Stock Market Inc., NETWORKING, New York Stock Exchange

• Naked Short Web Site Announces COE, CPN, HNP, KAL, OMNI, PDA Have Been Removed From Threshold Lists Today.

  - 2005-07-27

  M2 PRESSWIRE-27 July 2005-BUYINS.NET: Naked Short Web Site Announces COE, CPN, HNP, KAL, OMNI, PDA Have Been Removed From Threshold Lists TodayC1994-2005 M2 COMMUNICATIONS LTD RDATE:27072005 www.buyins.net, announced today that these select companies have been removed from the NASDAQ, AMEX and...

  Tags: AMEX, Callisto Pharmaceuticals Inc., Calpine Corp., COE, Handhelds, HARDWARE, Nasdaq Stock Market Inc., New York Stock Exchange, PDAs

Additional Resources

• Callisto Pharmaceuticals' Majority-Owned Subsidiary Synergy Pharmaceuticals Completes Phase I Trial of SP-304 in Volunteers

  - 2008-12-09

  Synergy Plans Major Push to Develop SP-304 to treat GI disorders NEW YORK -- Callisto Pharmaceuticals, Inc. (OTC BB:CLSP.OB), a developer of new drugs to treat cancer and gastrointestinal disorders, announced today that Synergy Pharmaceuticals (OTC BB: SGYP), its majority-owned subsidiary, successfully completed the Phase I clinical trial...

• Callisto Pharmaceuticals Announces $3.0 Million Financing by Its Synergy Pharmaceuticals Subsidiary and Related Transactions Leaving Callisto with a 68% Stake in Synergy

  - 2008-07-21

  NEW YORK -- Callisto Pharmaceuticals, Inc. (Pink Sheets: CLSP; FWB: CA4), announced today that its Synergy Pharmaceuticals, Inc. closed a $3.0 million private placement. The proceeds of the private placement will be used to fund the development of SP-304, its guanylate cyclase C (GC-C) receptor agonist, for chronic constipation CC...

• Pawfect Foods Announces Acquisition of Synergy Pharmaceuticals and $3.0 Million Financing

  - 2008-07-21

  Files Charter Amendment to Split Stock and Change Corporate Name NEW YORK -- Pawfect Foods, Inc., a Florida corporation (PWFF.OB) announced today that it acquired Synergy Pharmaceuticals, Inc. in exchange for shares of its common stock issued to Callisto Pharmaceuticals, Inc. (Pink Sheets: CLSP; FWB: CA4) and completed...

• Callisto Pharmaceuticals Opens Phase I Clinical Trial of SP-304 to Treat Chronic Constipation and Irritable Bowel Syndrome

  - 2008-06-04

  NEW YORK -- Callisto Pharmaceuticals, Inc. (AMEX: KAL; FWB: CA4) announced today that through its wholly-owned subsidiary, Synergy Pharmaceuticals, Inc., it initiated oral dosing of healthy volunteers in a Phase I clinical trial of SP-304. The primary objective of the Phase I clinical trial is to assess safety...

• Callisto Pharmaceuticals Reports Promising Interim Phase II Data for Atiprimod in Advanced Carcinoid Cancer

  - 2008-05-16

  NEW YORK -- Callisto Pharmaceuticals, Inc. (AMEX: KAL; FWB: CA4), a developer of new drug treatments in the fight against cancer and gastrointestinal disorders, announced today promising interim data from the company's ongoing open-label Phase II clinical trial of Atiprimod to treat low to intermediate grade neuroendocrine carcinoma (advanced carcinoid...

• Callisto Pharmaceuticals Announces Presentation on SP-304 at the 3rd International Congress on Natural Peptides to Drugs

  - 2008-04-15

  NEW YORK -- Callisto Pharmaceuticals, Inc. (AMEX: KAL; FWB: CA4), a developer of new drug treatments in the fight against cancer and gastrointestinal disorders, announced today that Dr. Kunwar Shailubhai, Sr. VP Discovery Research, will give a plenary talk covering therapeutic applications of guanylate cyclase C agonist peptides at the...

• Callisto Pharmaceuticals' Interim Phase II Data of Atiprimod in Advanced Carcinoid Cancer to be presented at ASCO Conference

  - 2008-04-14

  NEW YORK -- Callisto Pharmaceuticals, Inc. (AMEX: KAL; FWB: CA4), a developer of new drug treatments in the fight against cancer and gastrointestinal disorders, announced today that interim data from the company's ongoing open-label Phase II clinical trial of Atiprimod in advanced carcinoid cancer, will be presented at the 44th...

• Callisto Pharmaceuticals Files IND for SP-304 in Chronic Constipation and Irritable Bowel Syndrome

  - 2008-04-07

  NEW YORK -- Callisto Pharmaceuticals, Inc. (AMEX: KAL; FWB: CA4) announced today that through its wholly-owned subsidiary, Synergy Pharmaceuticals, Inc. it filed an IND on April 2, 2008 with the FDA for SP-304 also called Guanilib for the treatment of chronic constipation and constipation-predominant irritable bowel syndrome. SP-304...

• Callisto Announces Guanilib Presentation at the 5th Annual Meeting of Cancer Drugs Research and Development

  - 2008-02-19

  NEW YORK -- Callisto Pharmaceuticals, Inc. (AMEX: KAL; FWB: CA4), a developer of new drug treatments in the fight against cancer and gastrointestinal disorders, announced today that Dr. Kunwar Shailubhai, Sr. VP Discovery Research, will give an oral presentation covering preclinical data on Guanilib at the 5th Cancer Drugs Research...

• Callisto Pharmaceuticals to Present at the BIO CEO & Investor Conference

  - 2008-02-08

  NEW YORK -- Callisto Pharmaceuticals, Inc. (Amex: KAL; FWB: CA4), a developer of new drug treatments in the fight against cancer and gastrointestinal disorders, announced today that Gary S. Jacob, Ph.D., Chief Executive Officer of Callisto will present at the BIO CEO & Investor Conference on February 11-13, 2008 at...

• Edgeline Holdings Announces Donald Picker Has Joined the Company as Its Acting Chief Operating Officer

  - 2008-01-08

  HOUSTON -- Edgeline Holdings, Inc. (OTCBB:ELHI) announced today that Donald Picker has joined its subsidiary, Intertech Bio, as its acting Chief Operating Officer. Dr. Picker will assume the role of acting COO as of January 2008. Dr. Picker has extensive hands-on experience in bringing drugs from concept to...

• Callisto Pharmaceuticals Announces Investor Conference Call to Provide Details on Guanilib Strategic Initiative in GI Disorders

  - 2008-01-08

  NEW YORK -- Callisto Pharmaceuticals, Inc. (Amex: KAL; FWB: CA4), a developer of new drugs against gastrointestinal disorders and cancer announced today that it will hold an investor teleconference on January 14, 2008 at 10:00 AM EST to provide additional details regarding its strategic initiative to develop Guanilib for gastrointestinal...

• Callisto Pharmaceuticals Amends and Restates Atiprimod License Agreement with Genzyme

  - 2008-01-07

  New Agreement Eliminates Development Milestones and Significantly Reduces Royalties in Return for an Upfront Fee NEW YORK -- Callisto Pharmaceuticals, Inc. (Amex: KAL; FWB: CA4), a developer of new drug treatments in the fight against cancer and gastrointestinal diseases, announced today that it has restructured its license agreement...

• Incorporated: 2001
• CEO: Dr. Gary S. Jacob Ph.D.
• Employees: 11